(Q37339268)

19 August 2017

Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests (English)

1 reference

19 August 2017

0 references

0 references

1 reference

1

Soumya Swaminathan

0 references

Shashikant Srivastava

object named as

Shashikant Srivastava

series ordinal

5

0 references

Tawanda Gumbo

object named as

Tawanda Gumbo

series ordinal

8

0 references

Devyani Deshpande

series ordinal

6

object named as

Devyani Deshpande

1 reference

19 August 2017

2

Jotam G Pasipanodya

1 reference

19 August 2017

7

Eric Nuermberger

1 reference

19 August 2017

3

Geetha Ramachandran

1 reference

19 August 2017

A K Hemanth Kumar

4

1 reference

PMC publication ID

5064152

19 August 2017

language of work or name

English

0 references

publication date

1 November 2016

1 reference

Clinical Infectious Diseases

19 August 2017

1 reference

19 August 2017

63

1 reference

19 August 2017

suppl 3

1 reference

19 August 2017

S63-S74

1 reference

Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064152

Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064152

Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064152

Therapeutic drug monitoring in the treatment of tuberculosis: an update

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064152

Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064152

Serum drug concentrations predictive of pulmonary tuberculosis outcomes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064152

Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064152

Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064152

Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064152

An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064152

An introduction to recursive partitioning: rationale, application, and characteristics of classification and regression trees, bagging, and random forests

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064152

Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064152

Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064152

Nonlinear systems in medicine

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064152

Therapeutic drug monitoring in the treatment of tuberculosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064152

Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064152

Challenges in childhood tuberculosis.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064152

Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064152

In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064152

Identifying Important Risk Factors for Survival in Kidney Graft Failure Patients Using Random Survival Forests

2 September 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW471

Statistical Modeling: The Two Cultures (with comments and a rejoinder by the author)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW471

A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW471

Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW471

A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW471

21 January 2018

Identifiers

DOI

10.1093/CID/CIW471

1 reference

19 August 2017

1 reference

PMC publication ID

5064152

19 August 2017

PubMed publication ID

27742636

1 reference

PMC publication ID

5064152